easy 50% gain on table

The market is currently giving a negative value to PXS net of cash.

This is absurd.

There is value in the products, the pipeline, and actual sales. The pathway to US approval, albeit delayed, is now clear. The recent French setback, besides being non company specific, is arguably a positive as it further reduces cash burn.

No guarantees with any pharma, but surely a no brainer to find its way back to 20-25c, without assuming any heroics.

As confidence is slowly restored by the new management team, we can look at again at the blue sky on top.